Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

Massachusetts Financial Services Co. MA lifted its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 4.8% in the ...

Alector (NASDAQ:ALEC – Free Report) had its target price lowered by BTIG Research from $16.00 to $5.00 in a research note ...

Fintel reports that on November 26, 2024, Morgan Stanley downgraded their outlook for Alector (NasdaqGS:ALEC) from ...

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Mizuho says Alector’s (ALEC) top-line Phase 2 results for AL002 in Alzheimer’s disease “were non-equivocal, with negative signals on all ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

Alector shares are trading lower by 14.9% during Wednesday's session. The company announced the pricing of a $75 million public offering.

I spent four crazy years writing about Cassava Sciences, Adam Feuerstein writes. Yesterday, the story ended exactly as many ...

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...